Scolaris Content Display Scolaris Content Display

Depot risperidone for schizophrenia

This is not the most recent version

Collapse all Expand all

Abstract

available in

Background

Risperidone is the first new generation antipsychotic drug made available in a long acting injection.

Objectives

To examine the clinical effects of depot risperidone for people with schizophrenia and schizophrenia‐like psychoses.

Search methods

We searched the Cochrane Schizophrenia Group's Register (December 2002), references of all included studies, and contacted industry and authors of included studies.

Selection criteria

Randomised clinical trials comparing depot risperidone with other treatments for people with schizophrenia and/or schizophrenia‐like psychoses.

Data collection and analysis

Two reviewers independently inspected citations and/or abstracts, ordered papers, re‐inspected and quality assessed the results, and extracted data. For dichotomous data, we calculated the relative risk (RR), the 95% confidence interval (CI) and, where appropriate, the number needed to treat (NNT), on an intention‐to‐treat basis. For continuous data, we calculated weighted mean differences (WMD).

Main results

One study (n=400) compared depot risperidone with placebo but 56% of people did not complete the three‐month study rendering most global and mental state data unusable. Risperidone depot compared with placebo did not affect levels of anxiety (n=400, RR 0.58 CI 0.32 to 1.05) but may decrease agitation (n=400, RR 0.60 CI 0.39 to 0.92). Risperidone depot did not substantially influence hallucinations (n=400, RR 1.23 CI 0.47 to 3.22) but 'psychosis' was reduced (n=400, RR 0.52 CI 0.33 to 0.83, NNT 9 CI 7 to 26). Attrition was higher for the placebo group compared with people allocated risperidone depot (n=400, RR 0.74 CI 0.63 to 0.88, NNT 6 CI 4 to 12). Severe adverse events were common (13% to 23%) but significantly more so in the placebo group (n=400, RR 0.59 CI 0.38 to 0.93, NNT 11 CI 7 to 70). Poor reporting, however, makes these difficult to interpret. Movement disorders were equally common in both groups (n=400, RR 2.38 CI 0.73 to 7.78) although it looks as if there is a trend for the higher depot doses to encourage movement disorders.

One study (n=640) compared depot risperidone against oral risperidone for stable people with relatively mild illness. For global outcomes there was no clear difference between the depot group and oral group (n=640, RR 'no global improvement' 1.06 CI 0.92 to 1.22). Mental state measures were also similar across groups. Overall, in this study compliance was good (n=640, RR <4 injections or "major protocol violation" 1.16 CI 0.81 to 1.67). Adverse effects were poorly reported but over half of both groups reported some adverse effect (n=640, RR 1.04 CI 0.91 to 1.18).

Authors' conclusions

For reasonably well, stable people it may mean that the need for regular oral doses can be avoided, but adverse affects are not well reported. For more severely ill people, few benefits are evident although it may increase compliance with injections in comparison with placebo. Use of depot risperidone, especially at the higher doses, is weakly associated with movement disorders.

Well designed and reported, randomised studies, firmly grounded in real world clinical practice are needed to fully assess the effects of this new preparation.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

Plain language summary

available in

Depot risperidone for schizophrenia

Risperidone is the first atypical or new generation antipsychotic drug to be produced in long acting or depot form. This review identified only two studies, the results of which leave the reviewers in considerable doubt regarding the effects of this new preparation. Depot risperidone may more acceptable than placebo injection but it is hard to know if it is any more value in improving symptoms of schizophrenia. People already stabilised on oral risperidone may continue to maintain benefit if treated with depot risperidone, at least in the short term.